Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study.
about
Toxic epidermal necrolysis and Stevens-Johnson syndromeCarbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data reviewOxcarbazepine versus phenytoin monotherapy for epilepsyOxcarbazepine versus phenytoin monotherapy for epilepsyCarbamazepine versus phenytoin monotherapy for epilepsy.Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review.Rowell's syndrome in the course of treatment with sodium valproate: a case report and review of the literature data.Teicoplanin-induced hypersensitivity syndrome with a preceding vancomycin-induced neutropenia: a case report and literature review.Real-world efficiency of pharmacogenetic screening for carbamazepine-induced severe cutaneous adverse reactions.Lamotrigine-associated rash: risk/benefit considerations in adults and children.Lamotrigine. A review of its use in childhood epilepsy.Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review.Idiosyncratic reactions: new methods of identifying high-risk patients.Induction of hypersensitivity to a previously tolerated antiepileptic drug by a second antiepileptic drug.Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.Carbamazepine-induced acute liver failure as part of the DRESS syndrome.Antiepileptic drug hypersensitivity syndrome.Antiepileptic hypersensitivity syndrome: clinicians beware and be aware.Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.Lamotrigine update and its use in mood disorders.Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese.Clinical utility of eslicarbazepine: current evidence.Phenytoin-induced Lyell's syndrome.Anticonvulsant hypersensitivity syndrome: a review.Current understanding of delayed anticonvulsant hypersensitivity reactions.Adverse cutaneous reactions and drugs: a focus on antimicrobials.Drug reaction with eosinophilia and systemic symptoms syndrome in a patient taking phenytoin and levetiracetam: a case reportIntravenous immunoglobulin in the treatment of drug rash eosinophilia and systemic symptoms caused by phenytoinIdiosyncratic adverse reactions to antiepileptic drugs.Acute tubular necrosis as a part of vancomycin induced drug rash with eosinophilia and systemic symptoms syndrome with coincident postinfectious glomerulonephritis.Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine.Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care.Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome.Toxic epidermal necrolysis associated with antiepileptic drugs and cranial radiation therapy.Pharmacogenetic information derived from analysis of HLA alleles.First seizure - to treat or not to treat?Safety evaluation of topical valproate application.Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review.In vitro testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review.
P2860
Q21202877-118DF1C6-CC33-4C7D-AFD1-4F46147907C9Q24187872-95CE461E-45EA-4815-B80B-BA55FF0BAD0CQ24202768-26CBCCDF-8DE4-41EA-9D65-4E5096418ABBQ24246413-275409C4-5BB5-4D3F-BCC9-558AEAD72CC5Q31083753-D0028984-2EB8-4BA1-9728-5FBA24D1CEB9Q31166723-4D938EE3-5B93-4C34-A157-5F03666D76A7Q33387920-0AEE1AAB-3AC4-49C5-8096-D4A8F649941CQ33392706-A95FD5FF-C818-44D7-A4D6-8BB6024820E1Q33578364-28C1E187-7FF5-43F7-A0B7-7557D78DB8A3Q33685953-E1FCFAA0-4974-4E75-82FB-266906F6EA43Q34006439-BBDE4B64-8416-4A68-9B0D-F1E602B23090Q34013445-610139C2-B305-4C16-B1E7-BBAAF0ABDF89Q34090578-EA71A685-54DD-4415-AFED-D675962D16B6Q34301402-978A8685-2E2C-49C6-99F0-150016225650Q34345953-8CC51062-2D28-4CE8-879C-BF2295A6625EQ34408357-FD091F1E-4D59-4F48-BD1A-B2CFC3C99927Q34435476-F4D91CA7-C20D-4127-B859-0A3A42C057C1Q34478215-4A112F21-D010-4F25-BD04-1DA59FE52A86Q34564736-97152F7A-F92C-4BCB-A543-4E48B51129DBQ34598487-5DD86D5A-5D7D-43BE-A472-FDEF03075BD6Q34615607-E1B38BE2-2270-46D4-A7CC-0D9AD6381550Q34629177-205C6F67-F38F-41FC-A111-1BA307870BA2Q35087964-F89B6C17-6044-4B17-9A3A-8322CE88C227Q35982729-ED0B50D5-3719-41F2-BB35-1CA7EC2ACB6AQ36150584-1C0C15DD-7057-42F7-884D-9CEF2BCD8D32Q36444480-7BCA26D6-C48D-4A11-AC59-8E3DEFA74186Q36493557-6BF479DC-7FB4-46AE-97CD-BFC70AED5D57Q36531531-BC43BE19-6792-4C6E-9F9C-75A76655531EQ36543388-8E5C3898-131F-4BE2-8783-A2FB0B02A8FFQ36770454-8CA03EE7-42C7-4CAC-8638-4A439FF576E3Q36897302-D3F64F8D-0CCE-41B0-8422-5049B8120D4FQ36926122-1D271405-02F2-4957-9E45-ADDD5EA21C2EQ36952002-1640E602-C4ED-475A-8A72-CCD887849034Q37033603-0D550DCE-8755-49E5-8BD0-DB51FC3CD391Q37101175-67F14C6C-01D9-4710-B6B2-F56372A05B03Q37120841-CE56D0B5-E4C9-4D61-A5BE-13A400C9BC35Q37270800-17115349-8042-4FC4-BB63-4A7E13E67F4AQ37326512-003FEDEF-B2F5-46AB-8633-92F2F336ABC3Q37472027-87909CDA-4EB4-48E9-8020-A80929CBA060Q37605792-0AC4E29D-76F4-46F0-8F5E-5EB2C6FF7D60
P2860
Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study.
description
1997 nî lūn-bûn
@nan
1997 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Risk of serious cutaneous diso ...... roate: a record linkage study.
@ast
Risk of serious cutaneous diso ...... roate: a record linkage study.
@en
Risk of serious cutaneous diso ...... roate: a record linkage study.
@nl
type
label
Risk of serious cutaneous diso ...... roate: a record linkage study.
@ast
Risk of serious cutaneous diso ...... roate: a record linkage study.
@en
Risk of serious cutaneous diso ...... roate: a record linkage study.
@nl
prefLabel
Risk of serious cutaneous diso ...... roate: a record linkage study.
@ast
Risk of serious cutaneous diso ...... roate: a record linkage study.
@en
Risk of serious cutaneous diso ...... roate: a record linkage study.
@nl
P356
P1433
P1476
Risk of serious cutaneous diso ...... roate: a record linkage study.
@en
P2093
P304
P356
10.1212/WNL.49.2.542
P407
P577
1997-08-01T00:00:00Z